| Price | $31.49 |
| Year Range | $22.33 – $31.5 |
| Market Cap | $3.85B |
| PE Ratio | 18.2 |
| Industry | Biotechnology |
What Is Catalyst Pharmaceuticals’s AI Stock Analysis?
Catalyst Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Catalyst Pharmaceuticals’s momentum in near-real time.
Catalyst Pharmaceuticals (CPRX) has an AltIndex AI Score of 56/100, currently a Hold signal. The AI Score distills Catalyst Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Catalyst Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Catalyst Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving CPRX’s AI Score?
Fundamentals
Revenue for the last quarter was $153M. This is an increase of 2.84% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 7.61%, suggesting positive year-over-year growth. Net income for the last quarter was $53M. This represents a decrease of 0.16% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 5.79%, which may be a cause for concern. Ebitda for the last quarter was $81M. This is an increase of 0.76% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 12.12%, suggesting positive year-over-year growth. The current P/E ratio is 18.2. This appears to be within a normal range, neither particularly high nor low.
See Catalyst Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $31.49. This is equal to the stock price a month ago, showing short-term stability. Compared to a year ago, there is an increase of 59.36%, suggesting a positive long-term trend. The trend is neutral. The current SMA10 of $31.49 is equal to the previous SMA10, indicating no significant change in the trend. The RSI is 46.5, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Catalyst Pharmaceuticals is neutral. Catalyst Pharmaceuticals has an estimate of 8,000 visitors to their webpage. The number of visitors is down by -38% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Catalyst Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is high, a positive sign. Catalyst Pharmaceuticals has 870 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Catalyst Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Catalyst Pharmaceuticals AI Stock Analysis
Catalyst Pharmaceuticals's AltIndex AI Score is 56/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Catalyst Pharmaceuticals a Hold (56/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Catalyst Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the CPRX AI Score or sign up to read the full thesis.
